Accessibility Menu
Rhythm Biosciences logo

Rhythm Biosciences(ASX) RHY

Market CapA$31.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-69%
5 Year-92%
1 Year+5%
1 Month-12%
A$0.09
-2.30%
-0.00Today
Rhythm Biosciences last closing stock price
MetricPriceDate
Last closeAUD 0.092026-09-07
Rhythm Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.3%AUD 0.092026-08-31
1 month-12.37%AUD 0.102026-08-07
3 month-26.09%AUD 0.122026-06-09
Year to date-37.04%AUD 0.142025-12-31
1 year+4.94%AUD 0.082025-09-05
3 year-77.33%AUD 0.382023-09-08
5 year-92.06%AUD 1.072021-09-08
Since inception-68.67%AUD 0.282017-12-07

Rhythm Biosciences Financials at a Glance

Market Cap

A$31.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$3.28M

Net Income (TTM)

-A$9.76M

EPS (TTM)

-A$0.02

P/E Ratio

-4.92

Dividend

A$0.00

Beta (Volatility)

-0.02 (Low)

Price

A$0.09

Volume

0

Open

A$0.08

Previous Close

A$0.09

Daily Range

A$0.08 - A$0.09

52-Week Range

A$0.08 - A$0.28

Estimated Earnings Date

Feb 24, 2027

RHY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rhythm Biosciences

Rhythm Biosciences Limited is a forward-thinking enterprise focused on predictive cancer diagnostics, operating in both Australian and global markets. The company specializes in the development and commercialization of innovative medical diagnostic technologies, with a key product being ColoSTAT, a blood test designed for the early detection of colorectal cancer.

Products and Services
  • ColoSTAT: A specialized blood test for colorectal cancer detection
  • Innovative diagnostic technologies aimed at improving cancer outcomes
  • Research and development in predictive diagnostics
Growth Outlook
  • Significant market potential in cancer diagnostics, a growing healthcare sector
  • Recent advancements in ColoSTAT enhance competitive positioning
  • Strategic partnerships may accelerate product development and market entry
Financial Highlights
  • Recent quarterly revenue of AUD 46,247, showing growth potential
  • Cash and cash equivalents increased to AUD 1,643,309 in Q2 2025
  • Trailing twelve months (TTM) cash flow from operations indicates ongoing investment in R&D
Rhythm Biosciences Limited is positioned in a critical sector with a focus on innovative solutions for cancer diagnostics. The company's flagship product, ColoSTAT, represents a significant advancement in early cancer detection, which is crucial for improving patient outcomes. The growth outlook is bolstered by the increasing demand for effective diagnostic tools in the healthcare industry, alongside strategic initiatives that may enhance market presence. Financially, the company is navigating through a phase of investment in research and development, with recent quarterly results indicating a commitment to innovation and growth. The increase in cash reserves suggests a stable foundation for future endeavors, making Rhythm Biosciences a noteworthy entity in the medical diagnostics landscape.
AI Generated • Aug 23, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

CEO

David George Atkins, PhD, MBA

Website

www.rhythmbio.com

Headquarters

Parkville, VIC 3010, AU

RHY Financials

Key Financial Metrics (TTM)

Gross Margin

-5151.30%

Operating Margin

-8739.15%

Net Income Margin

-6948.85%

Return on Equity

-205.17%

Return on Capital

-191.96%

Return on Assets

-124.14%

Earnings Yield

-20.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$31.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

364.06M

Volume

0

Avg. Volume

252.17K

Financials (TTM)

Gross Profit

-A$4.02M

Operating Income

-A$11.26M

EBITDA

-A$10.80M

Operating Cash Flow

-A$8.15M

Capital Expenditure

-A$49.01K

Free Cash Flow

-A$8.20M

Cash & ST Invst.

A$3.44M

Total Debt

A$247.98K

Rhythm Biosciences Performance Analysis

Rhythm Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 25,126N/A
20262026-06-30AUD 85,339239.6%
Rhythm Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3130.8%
Q42025-06-30-99.2%
Q22025-12-3184.1%
Q42026-06-30-15.5%
Rhythm Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.04-9.5%
20242024-06-30AUD -0.03-19.1%
20252025-06-30AUD -0.01-52.7%
20262026-06-30AUD -0.0224.6%
Rhythm Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31119.7%
Q42025-06-30-778.3%
Q22025-12-3154.5%
Q42026-06-30-49.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$39.09K

-98.4%

Gross Profit

-A$2.26M

-286.4%

Gross Margin

-57.75%

N/A

Market Cap

A$31.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.38M

N/A

Employees

23

N/A

Net Income

-A$3.67M

-32.8%

EBITDA

-A$3.57M

-34.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$3.44M

+356.0%

Total Debt

A$247.98K

+51.4%

Accounts Receivable

A$64.27K

+72.8%

Inventory

A$16.30K

N/A

Long Term Debt

A$75.83K

-11.3%

Short Term Debt

A$172.15K

+119.7%

Return on Assets

-1.24%

N/A

Return on Invested Capital

-2.00%

N/A

Free Cash Flow

-A$3.04M

+1.7%

Operating Cash Flow

-A$3.01M

+2.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OSL.AXOncoSil Medical Ltd
A$0.91-12.92%
IIQ.AXINOVIQ Ltd
A$0.18-2.70%
BDX.AXBCAL Diagnostics Limited
A$0.07-2.90%
MAP.AXMicroba Life Sciences Limited
A$0.06+0.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About RHY

What is the current price of Rhythm Biosciences?

Rhythm Biosciences is trading at A$0.09 per share.

What is the 52-week range for Rhythm Biosciences?

Over the past 52 weeks, Rhythm Biosciences has traded between A$0.08 and A$0.28.

How much debt does Rhythm Biosciences have?

As of the most recent reporting period, Rhythm Biosciences reported total debt of A$247.98K.

How much cash does Rhythm Biosciences have on hand?

Rhythm Biosciences reported A$3.36M in cash and cash equivalents in its most recent financial results.

What is Rhythm Biosciences’s dividend yield?

Rhythm Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services